Unifrax Announces SiFAB™ Manufacturing Line
15.6.2021 14:00:00 EEST | Business Wire | Press release
Unifrax, a Buffalo, New York headquartered global manufacturer of high-performance specialty materials, announced plans today to build its first large-scale SiFAB (silicon fiber anode material) manufacturing line at its north central Indiana facility that could add up to 74 new jobs by the end of 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615005391/en/
SiFAB is a proprietary silicon anode battery technology which enables significantly greater energy density in lithium-ion battery systems than prevailing technologies. SiFAB is currently in advanced testing and has shown promising performance in multiple battery systems. The anode technology has successfully been tested with incremental Si loadings of greater than 40%. Along with greater energy density, SiFAB is expected to provide faster charges and longer battery life for applications including electric vehicles, portable electronics, power tools, energy grid storage and aerospace.
Unifrax is uniquely positioned to meet customer demand and develop SiFAB at scale, due to its existing manufacturing plant and infrastructure in New Carlisle. The Indiana plant will be the first to begin building SiFAB long-term manufacturing capacity. The new line is slated to create up to 20 new jobs by the end 2022, with additional growth anticipated by the end of 2023. Unifrax will have more information on open positions later this year on its website.
“SiFAB is the latest development using fiber-based technology to create step change value for customers. This transformational material represents another addition to our robust electric vehicle and battery solutions portfolio,” said John Dandolph, president and CEO, Unifrax. “Unifrax is a large, global manufacturing company introducing game changing advanced silicon anode materials that can be used in existing manufacturing processes. Our track record and proven ability to develop new and unique technologies will help transform the battery industry with SiFAB. The ability to leverage our existing facility and add new infrastructure to support SiFAB manufacturing in New Carlisle will significantly accelerate the timeline for supplying this critical material to our partners. We are appreciative of the ongoing partnership between the state of Indiana and St. Joseph County as we leverage the footprint of our existing facility to bring new jobs and opportunities to the region.”
“We designed SiFAB from its inception to be manufactured at large scale so that we could supply all market segments (EV’s, consumer electronics, power tools, and renewable storage), utilize our existing global manufacturing footprint, and deliver a product that has a high degree of quality and consistency,” said Chad Cannan, senior vice president of research and development, Unifrax.
The Indiana Economic Development Corporation offered Unifrax up to $1.1 million in conditional tax credits based on the company’s job creation plans. These tax credits are performance-based, meaning the company is eligible to claim incentives once Hoosiers are hired. St. Joseph County has also confirmed $775K in county tax incentives.
“Indiana is a leader in manufacturing, with the highest concentration of manufacturing jobs in the nation supported by 9,000 facilities across the state," said Jim Staton, interim secretary of commerce for the state of Indiana. “As new trends and technologies change the state of today’s manufacturing industry, Indiana is focused on partnering with forward-thinking companies like Unifrax to propel long-term growth in manufacturing and create quality career opportunities for Hoosiers.”
St. Joseph County Commissioner Andrew Kostielney also added, "The recent announcement by Unifrax is exciting news, not just for St. Joseph County, but for the entire region. Unifrax has long been an important manufacturing leader in the area, and this expansion indicates their commitment to our county for decades to come. Their new SiFAB line will not just create new jobs, it will also showcase the importance of green, sustainable technology."
After more than 75 years of experience in fiber-based technology and manufacturing, Unifrax is taking its first step into developing silicon fiber for the lithium-ion battery manufacturing market. With a decades-long track record of developing and supplying engineered inorganic materials at a large scale to advanced industries worldwide including electric vehicles, aerospace and chemical processing, Unifrax recently debuted two new fiber-based catalysis offerings for the automotive and industrial markets – Eco-lytic™ and FlexCat™.
To learn more about SiFAB, and to request a sample, Unifrax launched a new website introducing SiFAB with technical, manufacturing and application specific information. The new website can be found at sifab.com.
About Unifrax
Unifrax develops and manufactures high performance specialty materials used in advanced applications including high-temperature industrial insulation, electric vehicles, energy storage, filtration, and fire protection, among many others. Unifrax products are designed with the ultimate goal of saving energy, reducing pollution, and improving safety for people, buildings and equipment by delivering on our commitment to our customers of greener, cleaner, safer solutions for their application challenges. Unifrax has 37 manufacturing facilities operating in 12 countries and employs 2,700+ employees globally. More information is available at www.unifrax.com. For updates, follow us on Twitter, LinkedIn, and Facebook.
About Clearlake
Clearlake Capital Group, L.P. is a leading investment firm founded in 2006 operating integrated businesses across private equity, credit and other related strategies. With a sector-focused approach, the firm seeks to partner with experienced management teams by providing patient, long-term capital to dynamic businesses that can benefit from Clearlake’s operational improvement approach, O.P.S. ® The firm’s core target sectors are industrials, technology and consumer. Clearlake currently has approximately $39 billion of assets under management, and its senior investment principals have led or co-led over 300 investments. The firm has offices in Santa Monica and Dallas. More information is available at www.clearlake.com and on Twitter @ClearlakeCap.
About IEDC
The Indiana Economic Development Corporation (IEDC) leads the state of Indiana’s economic development efforts, helping businesses launch, grow and locate in the state. Governed by a 15-member board chaired by Governor Eric J. Holcomb, the IEDC manages many initiatives, including performance-based tax credits, workforce training grants, innovation and entrepreneurship resources, public infrastructure assistance, and talent attraction and retention efforts. For more information about the IEDC, visit www.iedc.in.gov.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005391/en/
Contact information
Media:
Deborah L. Myers (Unifrax) – dmyers@unifrax.com or 716.812.4802
Jennifer Hurson (Clearlake Capital) – jhurson@lambert.com or 845.507.0571
Erin Sweitzer (IEDC) – 317.296.2556 or esweitzer@iedc.in.gov
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
